Why Pfizer (PFE) Stock Is Trading Higher Today?
Pfizer's stock rose approximately 3% following reports of a White House initiative to sell discounted prescription drugs directly to consumers. The plan includes an agreement to offer Pfizer's medicines at lower prices and the launch of a site called TrumpRx for cash-paying customers. This initiative aims to reduce out-of-pocket costs and is linked to President Trump's most-favored-nation pricing policy. Pfizer is expected to lead the initial rollout, with industry groups monitoring the implementation closely.
Sep 30 - Pfizer stock jumped roughly 3% in morning trading after reports that the White House plans an initiative to sell discounted prescription drugs directly to U.S. consumers.
The Washington Post says the administration will unveil an agreement to offer Pfizer's medicines at lower prices, while The Wall Street Journal reports the government will launch a site called TrumpRx to let cash-paying customers buy drugs at government-negotiated discounts.
Under the plan, the administration would route some sales through Medicaid at reduced rates and permit purchases outside traditional insurance channels, aiming to lower out-of-pocket costs for patients. The move ties to President Trump's revived most-favored-nation (MFN) pricing policy, issued via executive order in May, and follows 60-day letters he sent in July to leaders at 17 major drugmakers requesting lower U.S. prices.
Pfizer appears positioned to lead an initial rollout, and rivals could join if the pilot proves workable. Industry groups and regulators will watch implementation details closely to assess impacts on access, insurers and federal programs.
